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A B S T R A C T
Objectives: To systematically review the literature on the unit cost and cost-effectiveness of malaria control.
Methods: Ten databases and gray literature sources were searched to identify evidence relevant to the period 2005 to 2018.
Studies with primary financial or economic cost data from malaria endemic countries that took a provider, provider and
household, or societal perspective were included.
Results: We identified 103 costing studies. The majority of studies focused on individual rather than combined interventions,
notably insecticide-treated bed nets and treatment, and commonly took a provider perspective. A third of all studies took
place in 3 countries. The median provider economic cost of protecting 1 person per year ranged from $1.18 to $5.70 with
vector control and from $0.53 to $5.97 with chemoprevention. The median provider economic cost per case diagnosed
with rapid diagnostic tests was $6.06 and per case treated $9.31 or $89.93 depending on clinical severity. Other
interventions did not share enough similarities to be summarized. Cost drivers were rarely reported. Cost-effectiveness of
malaria control was reiterated, but care in methodological and reporting standards is required to enhance data transferability.
Conclusions: Important information that can support resource allocation was reviewed. Given the variability in methods and
reporting, global efforts to follow existing standards are required for the evidence to be most useful outside their study
context, supplemented by guidance on options for transferring existing data across settings.
Keywords: cost-effectiveness, disease control interventions, malaria, unit cost.
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Introduction
No significant reduction in malaria burden has been recorded
since 2015, and in some countries, the disease burden is on the
rise.1 In 2018, 6 countries accounted for more than half of all
malaria cases (Nigeria, the Democratic Republic of the Congo,
Uganda, Côte d’Ivoire, Mozambique, and Niger), and children un-
der 5 years of age represented two thirds of the 405 000 malaria-
related deaths globally.1 The level of global investments in malaria
is reported to be below the estimated resource needs to achieve
progress targets.2-5 Under tight funding constraints, evidence on
the unit cost and cost-effectiveness of malaria control in-
terventions becomes ever more important, and how resources are
allocated comes under increasing scrutiny. We update previous
malaria control unit cost and cost-effectiveness reviews6-10 and
widen the scope of evidence by adding new data and in-
terventions with the aim to inform decision-making processes for
national malaria control strategies.
Methods
Search Strategy and Selection Criteria
We searched peer-reviewed studies from Medline, Embase,
Econlit, the National Health Service Economic Evaluation Data-
base, the Cost-Effectiveness Analysis Registry, Cochrane Library,
Web of Science, and the Latin American and Caribbean Health
Sciences Literature and gray literature from GreyNet/OpenSIGLE,
the Social Science Research Network, and the websites of the
World Bank Group, the World Health Organization (WHO), the
United States Agency for International Development, and Popu-
lation Services International. Searches were restricted to studies
published between January 1, 2005, and August 31, 2018. Before
2005, the set of malaria control interventions implemented by
countries was relatively limited; some of these interventions are
not recommended anymore, while others had very low coverage
and have since been replaced by different commodities. Our
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project started in June 2018, and we stopped searches in
September 2018. We used English search terms (see Appendix 1 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.
2021.01.013) only but considered studies published in English,
French, or Spanish. Reference lists of eligible studies were
reviewed and topic experts consulted to identify additional arti-
cles for inclusion. Studies included had to contain primary cost
data on 1 or more WHO-recommended malaria control in-
terventions and take a provider, provider and household, or so-
cietal perspective. Excluded were studies that: (1) exclusively
relied on mathematical modeling of cost data published by other
studies; (2) took a household perspective only; (3) were found in
poster presentation or conference abstract formats only; or (4)
pertained to the health of short-term travelers from non-endemic
to endemic countries. The study protocol was registered under
Prospero, number CRD42018105625.
Data Management and Analysis
Titles and abstracts were imported into the Covidence sys-
tematic review online management tool. Three reviewers inde-
pendently screened titles and abstracts, retrieved full texts of
potentially relevant studies, and assessed study eligibility for in-
clusion; discrepancies were resolved by a fourth reviewer. Review
team members extracted the data independently using a table
developed following discussions with investigators from the
Global Health Costing Consortium.11 Extracted data included: the
characteristics of each eligible study (first author, publication year,
country name, rural/urban or mixed study setting); details of the
studied intervention (type, delivery strategy, and/or platform;
population targeted; number of commodities distributed or area
covered if applicable); the analytical methods (study perspective,
including provider/household and provider or societal; financial
or economic cost; unit cost output measure, cost-effectiveness
health outcome measure where applicable); and the results
(unit cost or cost-effectiveness estimate; breakdown of unit cost
data by cost category, by resource input, and/or activity where
available).
When a study provided data for several years, only data from
the most recent year were extracted. If unit cost data were not
explicitly reported by studies, data on total cost and number of
commodities delivered or individuals covered by an intervention
were used. When the cost per treatment course was not reported
by a study, we estimated it using cost per dose data reported by
the study and WHO treatment recommendations to allow output
cost comparability across studies. Malaria treatment at outpatient
departments was considered uncomplicated malaria treatment,
whereas health facility admissions were assumed to be severe
cases. For graphical display, percentage unit cost category data
were converted to absolute terms.
Summary statistics were calculated by intervention, perspec-
tive, and unit cost output and/or cost-effectiveness health
outcome measure when more than 3 data points were available.
We present economic rather than financial data to better reflect
resource use. All cost data were converted to constant USD 2018.12
Cost data in currencies other than US dollars were first converted
from the local currency to US dollars using the exchange rate at
the year of costing before being inflated to 2018 USD.13
Results
The search yielded 16 985 records. Using Covidence, 6505
duplicates were removed. A further 9621 records were excluded
by title or abstract; 859 full-text articles were read and 754 were
excluded, of which 180 were duplicates previously unidentified by
Covidence, and 576 studies did not meet our inclusion criteria. A
total of 103 eligible studies were identified. This section summa-
rizes key results across eligible studies before describing in more
detail results by intervention type.
Overview of Results
Eligible studies concerned vector control interventions (n = 32,
31%), chemoprevention in special risk groups (n = 12, 12%), di-
agnostics (n = 18, 17%), treatment (n = 21, 20%), surveillance (n = 9,
9%), and combinations of 2 or more interventions (n = 11, 11%)
(Fig. 1). The number of eligible studies peaked at 14 in 2014 and
2017 (see Appendix 2 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2021.01.013). The eligible studies covered a
total of 39 countries, with one third of the studies concerned with
the unit cost and cost-effectiveness of malaria control in 3 sub-
Saharan African countries only, including Tanzania (n = 22),
Ghana (n = 13), and Zambia (n = 12) (Fig. 2). Fewer studies con-
cerned other regions, including the Eastern Mediterranean region
(n = 3), the Southeast Asia region (n = 3), the Western Pacific re-
gion (n = 5), and the region of the Americas (n = 4). Less than one
fifth (18%) of the eligible studies took place in 1 of the 6 countries
that together accounted for more than half of all malaria cases
worldwide in 2018.1 When interpreting the geographical distri-
bution and intervention type of studies, however, it is important
to note that among the eligible studies were both multi-country
(11%) and multi-intervention (11%) studies.
From a provider perspective, the median economic cost of
protecting 1 person from malaria ranged from $1.18 to $5.70 with
vector control and from $0.53 to $5.97 with chemoprevention. The
median provider economic cost per case diagnosed was $6.06 with
rapid diagnostic test (RDT) and $2.53 with microscopy, while it
was per case treated $9.31 and $89.93 for uncomplicated and
severe malaria, respectively. For surveillance and combinations of
interventions, the types of activities and the range of unit cost
output measures used in the eligible studies did not share enough
similarities to be summarized.
Vector Control
Vector control interventions include measures against malaria-
transmitting mosquitoes intended to limit mosquitoes’ ability to
transmit the disease. Vector control eligible studies investigated
the cost of the 2 core vector control interventions, including
insecticide-treated nets (ITNs) (n = 26, 81%),14-39 and/or indoor
residual spraying (IRS) (n = 3, 9%)23,37,40 or larval source man-
agement (LSM) (n = 5, 16%),41-45 a supplementary vector inter-
vention. Seven ITN,14,19-21,29,37-39 1 IRS,37 and 1 LSM43 studies were
also cost-effectiveness studies.
Insecticide-treated bed nets (ITN)
ITN are either conventionally treated nets that rely on peri-
odic retreatment of nets by dipping into an insecticide formu-
lation or factory-treated, pyrethroid-only, long-lasting
insecticide nets (LLINs) made of netting material with insecticide
incorporated within or bound around the fibers. A net needs to
retain its effective biological activity for 3 years of recommended
use under field conditions to qualify as an LLIN. Most ITN studies
considered pyrethroid-only long-lasting insecticide nets
(LLIN),15,16,18,19,22,24-29,31-36,38 the most common type of ITN
currently deployed, whereas others, published before 2009,
examined ITN with pyrethroid insecticide retreatment.17,21,30,37-39
More than half of ITN studies investigated continuous
distribution, while others (n = 9, 35%) analyzed campaigns (see
Appendix 3 in Supplemental Materials found at https://doi.org/
10.1016/j.jval.2021.01.013).
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Indoor-residual spraying (IRS)
IRS involves spraying interior surfaces of dwellings with a re-
sidual insecticide to kill or repel endophilic mosquitoes. Of the 3
eligible IRS studies, 1 concerned 2017 cost estimates of the United
States President’s Malaria Initiative IRS programs across 12
countries40 while the other 2 analyzed initiatives from 200623 or
before 200037 (see Appendix 3 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.013).
Larval source management (LSM)
LSM involves the management of aquatic habitats, which are
potential habitats for mosquito larvae, to prevent completion of
development of the immature stages. LSM studies concerned
larviciding,41-45 which is the regular application of biological or
chemical insecticides to water bodies. All but one42 were pub-
lished after 2010 41,43-45 (see Appendix 3 in Supplemental Mate-
rials found at https://doi.org/10.1016/j.jval.2021.01.013).
Unit cost and cost-effectiveness of vector control
interventions
From a provider perspective, the median economic cost per
person protected per year (PPPY) with ITN was US$1.39
(interquartile range [IQR] 0.72),25-27,34-36 with IRS $5.70
(IQR 2.0)37,39,40 and with larviciding $1.18 (IQR 0.54) (see
Appendix 3 in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2021.01.013).43-45 Additional unit economic cost
measures for ITN included $1.77 (IQR 1.46) per treated net year
(TNY)18,26,27,30,34-36 and $5.13 (IQR 3.76) per net distributed
(Appendix 3).14,16,18,20,21,25-27,29-37,39 Cost category data suggest
that nets represent nearly half of the cost per ITN distributed,
while once excluded, personnel is the main cost category, fol-
lowed by education/communication activities (IEC) and transport
(see Appendix 4 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.01.013). IRS and larviciding studies sug-
gested insecticide to be the largest cost category, followed for IRS
by project management and spray operations (see Appendix 5 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.
2021.01.013) and for larviciding by personnel (see Appendix 6 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.
2021.01.013).
Of all the interventions, ITNs had the most cost-effectiveness
data. ITN cost-effectiveness compared with no ITN was $5.85 per
episode averted (IQR 5.96)20 and, on average, $1281.97 (IQR
998.24) per death averted14,20,21,37-39 and $44.51 (IQR 35.04) per
Figure 1. PRISMA flow chart.
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DALY averted14,20,38,39 from a provider perspective across several
sub-Saharan African settings (Table 1). Using different insecticides
in South Africa and Mozambique, IRS cost-effectiveness compared
to no IRS, from the provider perspective, was $840.44 per death
averted and $25.16 per DALY averted.37 In a high-transmission
setting of Tanzania, larviciding cost-effectiveness compared to
no larviciding was $2.62 per case averted, $2412.17 per death
averted, and $46.87 per DALY averted from a societal perspective43
(see Appendix 3 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.01.013).
Chemoprevention
Chemoprevention is used for preventive treatment using
antimalarial medicines and aims to prevent malarial illness by
maintaining therapeutic drug levels in the blood throughout the
period of greatest risk.
Eligible studies concerned seasonal chemoprevention in chil-
dren (SMC) (n = 5, 42%)46-50 and intermittent preventive treat-
ment in pregnant women (IPTp) (n = 4, 33%)48,51-53 and in infants
(IPTi) (n = 3, 25%).47,50,54 Cost-effectiveness was explored by 2
studies each on SMC,48,49 IPTp,52,54 and IPTi55,56 (see Appendix 7
in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2021.01.013).
Chemoprevention eligible studies were all published
after 2009.
Seasonal chemoprevention in children (SMC)
SMC is recommended by the WHO for all children ,6 years
during each transmission season in areas with highly seasonal
malaria transmission in the sub-Sahel region of Africa. A SMC
course was defined as the first dose, given under observation, of
each treatment round. All studies had 3 or 4 treatment rounds,
with one also evaluating 6 rounds.49 SMC studies analyzed the
delivery costs of using community health workers (CHWs),46,47,50
volunteers,48,49 and/or mobile clinics46,47 or static facilities.47
Intermittent preventive treatment in pregnant women
(IPTp)
IPTp is recommended for all women in their first or second
pregnancy as part of antenatal care in malaria-endemic areas in
Africa. IPTp studies took place at antenatal clinics52,54,57 or in the
community.52,53
Intermittent preventive treatment of malaria in
infants (IPTi)
IPTI is recommended for infants (,1 year of age) at the time of
the second and third rounds of vaccination against DTP and
against measles in areas of moderate to high malaria transmission
in Africa. IPTi studies examined delivery at public health facilities
and/or EPI/mobile clinics.
Unit cost and cost-effectiveness of chemoprevention
From a provider perspective, the median economic cost per
child receiving a SMC course was $5.97 (IQR 6.79),46-50 and from a
societal perspective in Ghana it was $71.39,48 Training, supervision,
and distribution were the largest cost categories (see Appendix 8
in Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.01.013).46-49 The average cost per IPT dose administered to a
pregnant woman was estimated at $0.86 (95% CI 0.58-1.22),
including drug and personnel cost only.57 The societal cost per
Figure 2. Geographical distribution of eligible studies by intervention and study type.
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Table 1. Summary of cost-effectiveness data from eligible studies, by health outcome measure and intervention type (constant USD
2018).








Provider economic cost per episode averted
Median/min-max/
point estimate
$5.85 - - 4.38 - 121.50 0.30 1.28-389.82 79.25
Interquartile range
(IQR)
5.96 - - 5.67 - 121.81 1.47 N/A N/A
Number of point
estimates
3 0 0 15 0 10 6 2 1
Number of studies 220,21 0 0 255,56 0 248,49 192 1103 1100
Societal economic cost per episode averted
Median/min-max/
point estimate
$137.34* - 2.62 - - 177.34 30.99† - -
Interquartile range
(IQR)
N/A - N/A - - 160.28 2.34 - -
Number of point
estimates
1 0 1 0 0 4 6 0 0
Number of studies 119 0 143 0 0 248,49 192 0 0





- 271.13 - 3496.26 - - 39 628.04
Interquartile range
(IQR)
998.24 N/A - 73.84 - N/A - - N/A
Number of point
estimates
16 2 0 4 0 1 0 0 1
Number of studies 514,20,37-
39‡
137 0 156 0 148 0 0 1100
Societal economic cost per death averted
Median/min-max/
point estimate





N/A - N/A - - N/A N/A - -
Number of point
estimates
1 0 1 0 0 1 1 0 0
Number of studies 121,29 0 143 0 0 148 189 0 0
Provider economic cost per DALY averted
Median/min-max/
point estimate
44.51 23.22-27.09 - 10.41 - - 13.5 124.38-623.75 974.46
Interquartile range
(IQR)
35.04 N/A - 13.87 - - N/A N/A N/A
Number of point
estimates
14 2 0 14 0 0 1 2 1
Number of studies 314,20,38,39‡ 137 0 255,56 0 0 188 1102 1100
Societal economic cost per DALY averted
Median/min-max/
point estimate
- - 46.87 - 1.38-
50.17
- 105.59 - -
Interquartile range
(IQR)
- - N/A - N/A - N/A - -
Number of point
estimates
0 0 1 0 2 0 1 0 0
Number of studies 0 0 143 0 252,54 0 189 0 0
Summary statistics are presented when there were enough data (refer to number of studies for given category); otherwise point estimate or range are presented.
N/A indicates not applicable; –, no data; 6, all data for uncomplicated case treatment; ITN, insecticide-treated net; IRS, indoor residual spraying; IPTi, intermittent
preventive treatment for infants; IPTp, intermittent preventive treatment for pregnant women; SMC, seasonal malaria chemoprevention.
*Study of ITN hammock.
†Savings in treatment intervention using ACT compared with monotherapies91
‡Two references cover the same study37,39
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course of 2 IPTp doses ranged between $3.02 and $3.31 depending
on the delivery platform, with distribution and user costs reported
as main cost categories52 (see Appendix 7 in Supplemental Ma-
terials found at https://doi.org/10.1016/j.jval.2021.01.013). For IPTi,
the median economic cost per infant protected (having received 3
doses) was $0.53 (IQR 0.59) 51,55,56 with drug cost, training, and
IEC as the main unit cost categories (see Appendix 8 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2021.01.
013).
The cost-effectiveness of SMC was examined in Ghanaian set-
tings only: the median cost per episode averted using different
antimalarial drug regimens at community level was $121.50 (IQR
121.81) from a provider perspective and $177.34 (IQR 160.28) from
a societal perspective.48,49 The cost per death averted with SMC
was $3496 and $10 450 from a provider and societal perspective,
respectively48 (Appendix 7 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.013 and Table 1). Two studies
examined the cost-effectiveness of IPTp, both from the societal
perspective,52,54 with a median cost of $25.78 per DALY averted
(Appendix 7 in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2021.01.013 and Table 1). Finally, depending on the
drug regimen used, study location and transmission seasonality,
IPTi cost-effectiveness from a provider perspective ranged be-
tween $0.86 and $22.46 per malaria episode averted,55,56 $125.25
and $376.38 per death averted,56 and $3.51 and $47.95 per DALY
averted55,56 (Appendix 7 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.01.013 and Table 1), largely
driven by the very low unit cost of delivering the intervention.
Diagnosis
All suspected malaria cases should be confirmed with a para-
sitological test, including RDT or microscopy. Diagnostic eligible
studies examined RDT (17, 94%)58-74 and/or microscopy (n = 8,
50%)58-62,65,69,70,75 delivered to all-age presumptive malaria
cases,58-68,70,71,73-75 children under 5 years of age with fever,72 or
pregnant women69 at health facilities,58-63,65,67-70,72,74,75 drug
shops,64 or in the community66,71,73 (see Appendix 9 in Supple-
mental Materials found at https://doi.org/10.1016/j.jval.2021.01.
013).
Unit cost of diagnosis
Most studies analyzed the cost per case diagnosed and/or the
cost per case diagnosed and treated, while others also examined
the cost per additional case diagnosed and treated with RDT or
microscopy compared to presumptive diagnosis (n = 9) and/or the
cost per additional case diagnosed and/or treated with RDT/mi-
croscopy compared to microscopy/RDT (n = 3) (Appendix 9). Four
studies estimated RDT unit cost for different malaria transmission
risk59,65,66,68 or prevalence71 levels. (Appendix 9). From a provider
perspective, the median economic cost per case diagnosed with
RDT was $6.06 (IQR 6.23)59-61,65,69,72 and with microscopy $2.53
(IQR 5.24)59-61,65,69 The main cost categories included personnel,
commodities, and supplies (see Appendix 10 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.01.013).
Treatment
Five parasite species cause malaria in humans: Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium
ovale, and Plasmodium knowlesi. The first 2 pose the greatest
health threat.1 A patient with uncomplicated malaria is a patient
who presents with symptoms of malaria and a positive parasito-
logical test but with no features of severe malaria. Uncomplicated
malaria is assumed to be treated by outpatient health facility
services or at the community level. Severe malaria is generally
treated by inpatient healthcare services. Eligible treatment studies
related to malaria treatment in children and adults (except preg-
nant women in their first trimester) with uncomplicated malaria
or with severe malaria.
Studies examined the cost of treating Plasmodium falciparum
malaria (n = 18, 86%)76-93 or both Plasmodium falciparum and
Plasmodium vivax94-96 (Appendix 9). Cost-effectiveness was
analyzed in 5 studies.88,89,92,95,96 Most studies were published
after 201076,78,80-90,94,96 and concerned uncomplicated malaria
only,78,80,82-84,88,89,91-93,95,96 both uncomplicated and severe
malaria,76,79,81,86,90,94 with severe or moderate anemia81 or severe
malaria only77,85,87 in all ages,78,80,82,83,89,91,93 infants/
children,76,80,82,83,85,87-90,92,95,96 or pregnant or postpartum
women94 (Appendix 9). Studies examined the cost of treatment at
health facilities76-79,81,84-88,90,92,94-96 or in the
community,79,80,82,83,89,91,93 at times in the context of integrated
community case management.80,82,83 Cost data were commonly
reported per uncomplicated and/or severe case treated, occa-
sionally per case diagnosed and treated.83,92 A few studies also
examined the incremental cost or cost-effectiveness of different
antimalarial drugs79,87,88,92,95,96 or delivery platforms78,89
(Appendix 9).
Unit cost and cost-effectiveness of treatment
From a provider perspective, the median economic cost was
$9.31 (IQR 8.90) per uncomplicated case treated;76,78,79,82,84,88,90,94
$7.15 (IQR 2.77) per uncomplicated case diagnosed and
treated78,83,92 and $89.93 (IQR 51.10) per severe case treated
(Table 1).76,77,79,88,90,94 From a societal perspective, it was $11.90
(IQR 11.40) per uncomplicated case diagnosed and treated83,90,92
and $145.23 (IQR 118.88) per severe case treated.77,90 The largest
cost categories were personnel and drugs (see Appendix 11 in
Supplemental Materials found at https://doi.org/10.1016/j.jval.2
021.01.013).
The cost-effectiveness of treating uncomplicated malaria using
dihydroartemisinin-piperaquine compared to no treatment was
US$13.50 per DALY averted from a provider perspective in an ur-
ban district hospital of Tanzania88 (Appendix 9). In another district
hospital of Tanzania, the median provider cost-effectiveness of
artemisinin combination therapy compared to monotherapy was
$0.30 (IQR 1.47) per case averted and resulted in societal savings of
$30.99 (IQR 2.34) per case averted.92 In rural Ghana, the societal
cost-effectiveness of treating under-5 fevers at home using com-
munity health workers compared to routine treatment seeking
was $3025 per death averted and $106 per DALY averted89
(Appendix 9).
Surveillance
Surveillance is “the continuous and systemic collection, anal-
ysis and interpretation of disease specific data, and the use of that
data in the planning, implementation and evaluation of public
health practice.”97 In settings in which transmission is high, sur-
veillance is often integrated into broader routine health infor-
mation systems; where transmission is low and malaria is being
eliminated, surveillance is used to identify, investigate, and elim-
inate foci of continuing transmission, prevent and cure infections,
and confirm elimination. Surveillance studies concerned active
case detection (n = 5),98-102 surveillance systems for malaria epi-
demics (n = 2),103,104 and entomological surveillance (n = 2).105,106
Given the specificity of each surveillance intervention type, unit
cost and cost-effectiveness data are presently separately for each
intervention.
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Active case detection (ACD)
ACD is used to detect symptomatic cases that are not detected
by passive case detection (ie, when a person seeks care) and
asymptomatic cases in the community. ACD is generally con-
ducted intermittently outside health facilities by health workers
who visit patients at their houses, or elsewhere, and involves
administering a parasitological diagnosis of everyone in a targeted
population, immediate treatment to positive cases, and follow-up
to ensure complete cure.97 Proactive case detection (pACD) is
undertaken in populations that have limited access to facilities or
inadequate health-seeking behavior and in high-risk groups. Re-
active case detection (rACD) is undertaken in response to an in-
dex case (usually seen at a health facility), the epidemiological
characteristics of which trigger additional ACD, whereby a
household or a population potentially linked to the index case is
tested or screened for symptoms and tested before treatment.97
ACD studies were all published after 2011 and related to
rACD100,102 or pACD.98,99,101 The provider economic cost of rACD
was $38.63 per person tested and $32.07 per case treated100 and
for pACD $4.79 per person tested,101 $7.18 per person screened (ie,
tested and, if positive, treated),98 and $37.87 per case treated.101
Various types of cost output measures were used, and there was
not enough commonality across studies to review unit cost driver
data (see Appendix 12 in Supplemental Materials found at https://
doi.org/10.1016/j.jval.2021.01.013). The incremental cost-
effectiveness of pACD was $79.25 per case averted, $39 628 per
death averted, and $623.75 per DALY averted compared to no pro-
ACD.101 No study examined the cost-effectiveness of rACD.
Surveillance systems for epidemics
Studies on surveillance systems for epidemics were published
before 2010.103,104 The provider economic cost ranged from $0.04
per person per year to $1.47 per person protected and cost-
effectiveness between $1.28 and $389.82 per case averted
depending on transmission intensity (Appendix 12).104
Entomological surveillance
Entomological studies were published after 2011 and con-
cerned the provider cost of community-based mosquito trapping
schemes.105,106 Unit cost measures included the cost per person-
night of sampling and the cost per specimen of Anopheles
caught (Appendix 12). None of the studies provided data on the
cost-effectiveness of these interventions using a health outcome
measure.
Combinations of Malaria Control Interventions
Eleven studies examined more than one type of intervention,
and all were published on or after 2012, except one (see Appendix
13 in Supplemental Materials found at https://doi.org/10.1016/j.
jval.2021.01.013).107-117 Studies investigated the cost or cost-
effectiveness of combining preventive interventions
only,108,109,111-114,116 commonly vector control108,113,114,116 in sub-
Saharan African settings, while others examined the unit cost of
more comprehensive intervention packages in relatively low
endemic or elimination settings107,110,114,115,117 (Fig. 2). These latter
studies also analyzed the incremental cost-effectiveness of adding
1 or more interventions to routine activities.107,117 Given the var-
iable focus of these studies and the different unit cost output and
cost-effectiveness outcome measures, no summary statistics could
be calculated.
Discussion
This review identified 103 studies with primary data on the
unit cost of delivering the currently WHO-recommended malaria
control interventions, either individually or in combination, with
approximately one third of the studies also providing evidence on
the cost-effectiveness of these interventions. Summarizing the
available evidence was a challenge given the high degree of het-
erogeneity within and across the studied interventions. Overall,
cost-effectiveness studies reiterated the value for money of ma-
laria control, although global efforts in methodological and
reporting standards are required for the evidence to be useful
outside their study contexts.118-123 These results are important
when considering how unit costs and cost-effectiveness data from
one study are frequently used in different settings with limited or
no adaptation.
The available evidence also concerned largely individual in-
terventions and less so that of comprehensive packages of in-
terventions, which is recommended for effective control.4 The
number of studies of malaria control interventions in combination
increased in recent years, although these studies appeared to be
more common in lower-transmission settings and designed to
assess the incremental cost-effectiveness of adding one inter-
vention on top of another one. These studies shine little light on
the change in efficiency of combining the delivery of in-
terventions. The 2 studies that allowed for the comparison of
delivering interventions separately or in combination108 with ITNs
and IRS and with ITNs and IPTp109 suggest the cost savings of
combining the delivery of both is minimal. It was difficult to
compare the other packages of interventions within the studies
themselves, or to the wider cost and cost-effectiveness literature
due to the way the data were presented. As health systems move
toward more integrated service delivery, it will be important that
future cost and health outcome data allow for analyses of effi-
ciency gains and economies of scope. Few studies examined ma-
laria control interventions in the presence of comorbidities. For
instance, only 1 study used anemia reduction as an outcome of
malaria control despite the close link between the 2 conditions.124
Studies also rarely explicitly considered the quality of in-
terventions or their equitable coverage when examining unit cost
or/and cost-effectiveness.
Our systematic review has some limitations. Non-English
search terms and conference abstracts or posters were
excluded as well as modeling studies relying exclusively on
secondary unit cost or cost-effectiveness data. Study heteroge-
neity, in terms of analytical perspective, type of cost, unit cost
output, and/or cost-effectiveness comparator made it impossible
to generate summary statistics for all interventions. Cost-
effectiveness results are influenced by the coverage rate of the
intervention under investigation, access to other control in-
terventions, and wider health system characteristics. However,
these details were rarely reported in the eligible studies. Most
studies were conducted within trial contexts as opposed to
routine delivery, which may distort unit cost, cost drivers, and
cost-effectiveness results. Often, costing studies reported point
estimates and not ranges, which likely reflect the real-world
uncertainty associated with costing parameters. Such frustra-
tions with costing and cost-effectiveness literature are not
unique to malaria control interventions.119,125 Finally, a quality
assessment or risk of bias assessment was originally planned as
part of the study. Having reviewed and piloted various
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tools,126-131 it became apparent that they were not suitable, and
indeed led to misleading findings. The tools were designed for
cost-effectiveness studies with both costs and outcome data
primarily from trials as the default. Our review, however, con-
tains both costing and cost-effectiveness studies, and the purely
costing studies “scored” consistently lower given they did not
cover all the domains. We, therefore, chose not to undertake a
quality assessment using a tool that was not fit for the purpose,
nor did we think it insightful to develop a bespoke tool for
this study given issues of external validity.131 Deeper reflections
on assessing the quality of these data is an important next
step.
Conclusions
To our knowledge, this is the first systematic review to identify
and examine the unit cost and cost-effectiveness of all WHO-
recommended interventions, implemented individually or in
combinations. We identified 103 different costing studies, with
nearly one third analyzing the cost-effectiveness of malaria con-
trol. The most commonly examined malaria control intervention
was ITN, with 26 costing studies and 7 ITN cost-effectiveness
analyses, followed by treatment with 21 costing and 5 cost-
effectiveness studies. Tanzania, Zambia, and Ghana were by far
the most common study settings. The number of studies on
combinations of interventions increased recently, although most
focused on lower-transmission settings or preventive in-
terventions. Our results indicate that studies used more frequently
a provider perspective with more limited societal considerations.
Looking to the future, more standardized methods and reporting
are needed, as well as guidance on options to transfer data across
contexts.
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